Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  CVS Health Corporation    CVS

CVS HEALTH CORPORATION

(CVS)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

CVS Health : U.S. judge concerned over government nod for CVS-Aetna deal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/04/2018 | 03:16pm EDT
FILE PHOTO: The CVS logo is seen at one of their stores in Manhattan, New York, U.S.

WASHINGTON (Reuters) - A federal judge who has been asked to sign off on the U.S. government's decision to approve CVS Health Corp's acquisition of insurer Aetna Inc said Tuesday he was "less convinced" than the government that the companies had struck a deal that ensured the merger was legal under antitrust law.

Judge Richard Leon of the U.S. District Court for the District of Columbia had complained last week in a hearing that the two sides had treated him as a "rubber stamp" for the agreement. CVS closed the $69 billion transaction last week and began the integration process.

"At this stage, I am less convinced of the sufficiency of the government's negotiated remedy than the government is," he wrote in the order issued on Tuesday.

The Justice Department approved the merger of CVS, a pharmacy chain and benefits manager, and Aetna on condition that the health insurer sell its Medicare Part D drug plan business to WellCare Health Plans Inc. That sale was completed last month.

Also in the order, Leon asked the government and the companies to file a brief by Dec. 14 to show why their integration should not be halted while he considers whether or not to approve the consent decree reached in October.

Most consent agreements that the antitrust agencies strike with companies to resolve competitive concerns are approved by federal courts with little fuss under the 1974 Tunney Act, which requires courts to ensure the agreements are in the public interest.

Companies generally do not wait for final court approval before closing their transactions.

(Reporting by Diane Bartz; Editing by Bernadette Baum)

Stocks mentioned in the article
ChangeLast1st jan.
CVS HEALTH CORPORATION 0.98% 53.52 Delayed Quote.-18.32%
WELLCARE HEALTH PLANS 0.95% 279.65 Delayed Quote.18.45%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORPORATION
12:01pCVS HEALTH : To Host 2019 Investor Day For The Investment Community
PR
05/17CVS HEALTH CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/15NEWS HIGHLIGHTS : Top Company News of the Day
DJ
05/15CVS HEALTH : to Require Third-Party Testing of Vitamins, Supplements
DJ
05/15CVS PHARMACY : Launches 'Tested to Be Trusted' Program for Vitamins and Suppleme..
PR
05/09CVS PHARMACY : Completes Rollout of Time Delay Safes in All of Its Minnesota Pha..
PR
05/06PREMIER : to Exit Specialty Pharmacy Operations in Deal With CVS Unit
DJ
05/06EXCLUSIVE : Hedge funds target Centene, may oppose WellCare deal - sources
RE
05/02CVS HEALTH : to Close 46 Pharmacy Locations - Update
DJ
05/02CVS HEALTH : to Close 46 Pharmacy Locations
DJ
More news
Financials ($)
Sales 2019 252 B
EBIT 2019 14 336 M
Net income 2019 6 545 M
Debt 2019 64 157 M
Yield 2019 3,75%
P/E ratio 2019 10,56
P/E ratio 2020 9,37
EV / Sales 2019 0,53x
EV / Sales 2020 0,49x
Capitalization 68 852 M
Chart CVS HEALTH CORPORATION
Duration : Period :
CVS Health Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CVS HEALTH CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 69,0 $
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
Eva C. Boratto Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors